Journal
JOURNAL OF NEURAL TRANSMISSION
Volume 115, Issue 8, Pages 1181-1187Publisher
SPRINGER WIEN
DOI: 10.1007/s00702-008-0080-1
Keywords
Cu; Alzheimer; clinical trial; ADAS-cog; MMSE
Categories
Funding
- HOMFOR program of the Saarland University Medical Faculty
Ask authors/readers for more resources
Disturbed copper (Cu) homeostasis may be associated with the pathological processes in Alzheimer's disease (AD). In the present report, we evaluated the efficacy of oral Cu supplementation in the treatment of AD in a prospective, randomized, double-blind, placebo-controlled phase 2 clinical trial in patients with mild AD for 12 months. Sixty-eight subjects were randomized. The treatment was well-tolerated. There were however no significant differences in primary outcome measures (Alzheimer's Disease Assessment Scale, Cognitive subscale, Mini Mental Status Examination) between the verum [Cu-(II)-orotate-dihydrate; 8 mg Cu daily] and the placebo group. Despite a number of findings supporting the hypothesis of environmental Cu modulating AD, our results demonstrate that oral Cu intake has neither a detrimental nor a promoting effect on the progression of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available